title: The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update.
abstract: The Alzheimer's Disease Neuroimaging Initiative (ADNI), launched in 2004, has worked to accelerate drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the initiative has set a new standard for data sharing without embargo and for the use of biomarkers in dementia research. The ADNI effort in North America is not the only such effort in the world. The Alzheimer's Association recognized these global efforts and formed Worldwide ADNI (WW-ADNI). By creating a platform for international collaboration and cooperation, WW-ADNI's goals are to harmonize projects and results across geographical regions and to facilitate data management and availability to investigators around the world. WW-ADNI projects include those based in North America, Europe, Japan, Australia, Korea, and Argentina.
authors.affiliation: Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: jhendrix@alz.org.
authors.forename: James A
authors.initials: JA
authors.lastname: Hendrix
authors.affiliation: Independent Science Writer, Evanston, IL, USA.
authors.forename: Brad
authors.initials: B
authors.lastname: Finger
authors.affiliation: Center for Imaging of Neurodegenerative Diseases (CIND), Northern California Institute of Research, San Francisco VA Medical Center, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Weiner
authors.affiliation: Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
authors.forename: Giovanni B
authors.initials: GB
authors.lastname: Frisoni
authors.affiliation: Department of Neuropathology, Graduate School of Medicine, the University Hospital of Tokyo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Iwatsubo
authors.affiliation: Department of Molecular Imaging, Austin Health, Melbourne, Australia.
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Rowe
authors.affiliation: Department of Psychiatry, Asian Medical Center, Seoul, Republic of Korea.
authors.forename: Seong Yoon
authors.initials: SY
authors.lastname: Kim
authors.affiliation: Aging and Memory Center, Instituto de Investigaciones Neurologicas Raul Carrea (FLENI), Buenos Aires, Argentina.
authors.forename: Salvador M
authors.initials: SM
authors.lastname: Guinjoan
authors.affiliation: Aging and Memory Center, Instituto de Investigaciones Neurologicas Raul Carrea (FLENI), Buenos Aires, Argentina.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Sevlever
authors.affiliation: Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Carrillo
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D014943:Global Health; D006801:Humans; D059906:Neuroimaging
chemical_list: D015415:Biomarkers
keywords: Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Neuroimaging